Global Diabetes and Obesity Therapeutics, 2024 2028: Lucrative Market Opportunities with GLP-1-based Multi-agonistsGLP-1-based Multi-agonists with Improved Tolerability Profile - ResearchAndMarkets.com
2024-07-19
This study aims to identify the primary growth opportunities that will drive the diabesity market in the near future. The study also aims to highlight the most prominent and emerging business models prevalent across the market that will enable industry stakeholders to enhance their geographic coverage in terms of patient outreach and address the challenges of limited patient access.
Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with healthcare has grown and is predicted to continue. The demand for combination treatments that address obesity and diabetes (diabesity) jointly has increased notable as a result of these healthcare challenges.
Current drug therapies for obesity have a limited safety and efficacy profile. Furthermore, patient-centricity and variability in disease management are lacking. These gaps in available therapies will lead to increased demand for newer classes of drugs, such as GLP-1 receptor agonists, that have emerged as breakthrough drug classes and offer superior glycemic control and weight loss, resulting in better clinical outcomes. Owing to a surge in demand globally, R&D efforts by market participants will intensify. Strategies to improve supply, affordability, and access to these therapies for a wider patient population while preventing off-label sales will drive direct-to-consumer and hybrid care models.
Life sciences companies are likely to augment their research efforts to develop safe and efficacious pharmacological therapies with a focus on lowering the dosing frequency, sustained weight loss without lean muscle loss, benefits across the cardiometabolic spectrum, and drug delivery innovations as key competitive differentiation strategies.
The trend of strategic research partnerships is poised to accelerate the development of next-generation medicines, novel drug classes with new mechanisms of action, and beyond-the-pill solutions. In addition, a patient-centric treatment approach will be adopted that will combine pharmacotherapy with nutrition, behavioral, and lifestyle interventions for managing cardiometabolic diseases. Hence, in the next 2 to 3 years, pharma companies will increasingly launch digital services to improve patient access in partnership with telehealth platforms for personalized treatment management.
In addition, the focus on precision medicine (PM) will rise in the next 5 years, leading to better disease management. This will continue to drive PM research by small biotechs and market leaders. For example, the Novo Nordisk Foundation Centre for Genomic Mechanism of Diseases partners with academia and research institutes such as the Broad Institute of Cambridge to map human gene regulation in obesity and diabetes.
The study will also shed light on some of the crucial market drivers and restraints that impact growth. It provides brief yet significant insights into the game-changing participants across each indication that are striving to develop disruptive drugs and technologies to maintain their growth trajectory. The study focuses on the leading M&A and partnership activities that are impacting the market as well as present and future market trends that will shape its future. The study period is 2021 to 2028.
Growth Opportunity Universe
GLP-1-based Multi-agonists with Improved Tolerability Profile
AI-driven Predictive and Personalized Care in Diabesity
Obesity Therapeutics Development in India and China
Key Topics Covered:
Why is it Increasingly Difficult to Grow?
The Strategic Imperative
Ecosystem
Projected Prevalence - Obesity
Economic Burden - Obesity
Projected Regional Prevalence - Diabetes
Economic Burden - Diabetes
Trends Advancing Market Growth
Drug Development Trends - Obesity R&D Pipeline
Drug Development Trends - Diabetes R&D Pipeline
Impact and Market Disruptions - GLP-1 Drug Class
Scope of Analysis
Segmentation by Product
Competitive Environment
Key Competitors
Growth Generator
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Considerations
Revenue Forecast
Revenue Forecast by Product
Revenue Forecast by Region
Revenue Forecast Analysis
Market Outlook - GLP-1 Therapy Access
Forecast Analysis by Region
Pricing Trends and Forecast Analysis
Revenue Share
Revenue Share Analysis
Investment Trends - Capability Building and R&D Focus
Consolidation Trends - Pipeline Buildup and Market Penetration
Business Models
Hybrid Care Model for GLP-1 Drugs
Companies to Watch - Obesity
Companies to Watch - Diabetes
Companies to Watch - Virtual Solution Providers for GLP-1 Drugs
Growth Generator - Obesity Therapeutics
Growth Metrics
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Forecast Analysis by Region
Revenue Forecast by Pharmacological Class
Forecast Analysis by Pharmacological Class
Growth Generator - Diabetes Therapeutics
Growth Metrics
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Forecast Analysis by Region
Revenue Forecast by Pharmacological Class
Forecast Analysis by Pharmacological Class
Best Practice Recognition
Next Steps
Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
List of Exhibits
A selection of companies mentioned in this report includes, but is not limited to:
Broad Institute of Cambridge
Novo Nordisk Foundation Centre for Genomic Mechanism of Diseases
For more information about this report visit https://www.researchandmarkets.com/r/94mzqo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。